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The aim of this study was identiﬁcation of the immunologic markers of the damage to the eye apparatus at early stages of dia-
betes mellitus (DM) type 1 children. One hundred and eleven children with DM type 1 were divided into two groups: those with
nonproliferative diabetic retinopathy (NPDR) and without retinopathy. All the children had their daily urine albumin excretion,
HbA1c, C-peptide measured, 24-hour blood pressure monitoring, and ophthalmologic examination. Levels of TNF-α,I L - 6 ,a n d
IL-12 in serum were measured by ELISA tests (Quantikine High Sensitivity Human by R&D Systems, Minneapolis, Minn, USA).
The NPDR children demonstrated a signiﬁcantly longer duration of the disease in addition to higher HbA1c, albumin excretion
r a t e ,C - r e a c t i v ep r o t e i n ,s y s t o l i cb l o o dp r e s s u r e ,a sw e l la sT N F - α and IL-6 levels than those without retinopathy. The logistic re-
gressionrevealedthattheriskofNPDRwasstronglydependentonTNF-α[(OR4.01;95%CI2.01–7.96)].TNF-αappearstobethe
most signiﬁcant predictor among the analyzed parameters of damage to the eye apparatus. The early introduction of the TNF-α
antagonists to the treatment of young patients with DM type 1 who show high serum activity of the TNF-α may prevent them
from development of diabetic retinopathy.
Copyright © 2007 Katarzyna Zorena et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Diabetic retinopathy usually does not occur during the ﬁrst
ﬁve years from the diagnosis of diabetes mellitus (DM) type
1, whilst after 10 years of diabetes it is present in over 50%
of patients, being the most common cause of loss of vi-
sion[1].Regardlessnumerousstudiescarriedoutworldwide,
daily urine albumin secretion remains to be standard marker
of nephropathy development, while ophthalmologic exam-
ination stands for diagnosis of retinopathy [2, 3]. Presently,
thereisnosatisfactorypharmacologictherapyandlaserther-
apy remains to be the leading treatment option in manage-
ment of DM1 retinopathy in children. Yet still the therapy is
aimed at limiting the damage and not at preventing it [3, 4].
Early detection of the individual tendency for development
of diabetic retinopathy, especially before evident changes be-
come visible at the fundus of the eye, is extremely signiﬁ-
cant in children and adolescent with DM type 1. Most of the
published works focus on the role of cytokines in the de-
velopment of proliferative retinopathy in adults, thus such
analysis is limited to the late stages of the retinopathy [5–
8]. It has been suggested that hyperglycemia may lead to the
activation of proinﬂammatory cytokines that are crucial for
development and progression of retinopathy [9, 10]. One of
the glucose toxic mechanisms, the protein glycation, is as-
sociated with cytokines: tumor necrosis factor-alpha (TNF-
α), interleukin-6 (IL-6), and interleukin-12 (IL-12) that are
substantial factors in the development of diabetic microan-
giopathy[9–11].TNF-αandIL-6mayactaslocalintensiﬁca-
tion signals in pathological processes associated with chronic
eye inﬂammation [5, 6]. It has been shown in NOD-mice
that also IL-12 is associated with rapid diabetes development
[12]. Therefore, the purpose of this work was the identiﬁca-
tion of the early immunologic markers of the damage to the
eye apparatus in diabetic children.
2. PATIENTS AND METHODS
One hundred and elevenchildren (age15±2y ear s )wi t hD M
type 1 were recruited from The Diabetological Department,2 Mediators of Inﬂammation
Clinic of Pediatrics, Hematology, Oncology and Endocrinol-
ogy Medical University of Gda´ nsk. Type 1 DM, was deﬁned
in accordance with the criteria of the American Diabetes As-
sociation [13, 14].
3. LABORATORY EXAMINATIONS
HbA1c was measured by an immunoturbidometric method
using Unimate 3 set (Hoﬀmann-La Roche AG, Germany)
with a normal range of values 3.0–6.0%. Fasting glucose was
measuredbyenzymatic test(RocheDiagnostics GmbH,Ger-
many). Level of CRP was measured with immunochemical
system (Beckman Instr. Inc., Ireland). Level of C-peptide was
below 0.5ng/ml in all children with type 1 DM. The systolic
anddiastolicbloodpressuresweremeasuredusingautomatic
24-hour ambulatory blood pressure monitoring (ABPM)
and all the average values of the blood pressure were ex-
pressed in the centile charts. The urinary albumin excretion
was expressed as the average of the three 24-hour collections
obtained during 6 months prior to the enrolment into the
study. Classiﬁed as microalbuminuria were the cases when
at least in two out of three urine samples albumin excre-
tion was between 30–299 mg/24 hours. The urinary albumin
excretion is measured by immunoturbidometric assay us-
ing Tina-quant (Boehringer Mannheim GmbH, Germany).
Serum level of creatinine was measured using CREA assay
system (Boehringer Mannheim GmbH, Germany). All pa-
tientswithtype1DMrequiredinsulintreatment(0.87±0.24
U/kg of the body weight).
4. OPHTHALMOLOGIC EXAMINATION
In all children with type 1 DM the ophthalmologic investi-
gation was performed. This included visual acuity tests, in-
traocular pressure, and anterior segment estimation done by
slit lamp (TOPCON SL-82, Japan). The fundus examina-
tion was done after installation of 1% Tropicamid to obtain
suﬃcient mydriasis. The examination was performed by us-
ing the +90D lens (Ocular Instruments Inc., Bellevue, Wash,
USA). Digital camera (Topcon IMAGEnet 2000 Japan) was
used to perform the ﬂuorescein angiography.
The analysis of the eye fundus pictures was based on The
International Diabetic Retinopathy Division: 1) nonprolifer-
ative retinopathy with or without maculopathy, 2) prepro-
liferative retinopathy, 3) proliferative retinopathy [15]. Ac-
cording to the ophthalmological examination, the diabetic
children were divided into 2 groups: with diabetic retinopa-
thy (21 children) and without retinopathy (90 children).
In 21 cases, typical symptoms of nonproliferative diabetic
retinopathy were proven. Additionally, 16 children of the
group with nonproliferative diabetic retinopathy had mi-
croalbuminuria and 7 children were presented with arterial
hypertension, while none of the children without retinopa-
thy presented clinical signs of diabetic nephropathy such as
microalbuminuria or arterial hypertension.
A group of 41 healthy children (age 14 ± 2y e a r s )v o l -
unteered as the control group. They were apparently healthy
as based on their medical examination. Written, informed
consent was obtained from all children (or from their par-
ents) participating in the study. This study was approved by
The Ethics Committee of The Medical University of Gda´ nsk
NKEBN/610/2003/2004 and the investigation was carried
out in accordance with the principles of the Declaration of
Helsinki as revised in 1996.
5. SAMPLE COLLECTION
Plasma samples were collected from the 152 children. Blood
samples were immediately placed on ice, clariﬁed by cen-
trifugation at 3.000×g f o r5m i n u t e sa t4 ◦C, and kept frozen
at −80◦C until assay.
6. DETERMINATION OF TNF-α, IL-6, IL-12 LEVELS
Serum levels of cytokines TNF-α IL-6, IL-12 were measured
byimmunoenzymaticELISAmethod(QuantikineHighSen-
sitivity Human by R&D Systems, Minneapolis, Minn., USA)
according to manufacturer protocol. Minimum detectable
concentrations were determined by the manufacturer as 0.12
pg/ml, 0.03 pg/ml, and 1.0 pg/ml, respectively. Intra-assay
(2.6 for TNF-α; 1.6 for IL-6; 1.1 for IL-12) and interassay
(7.4 for TNF-α; 6.4 for IL-6; 7.1 for IL-12) precision perfor-
mances of the assays were determined on 20 replicates from
the quality control data of the laboratory.
7. STATISTICAL ANALYSIS
The results were analyzed using The Statistical Version 7.0
program(StatSoftPolska).TheShapiro-Wilktestwasusedto
evaluate normality of variables. The diﬀerences between the
groups were calculated with Student t or the nonparametric
U-Mann-Whitney tests.
A logistic forward regression analysis was used to assess
the association between all clinical and inﬂammatory pa-
rameters and retinopathy with a P<. 05 for entry. Risk for
retinopathy was estimated by odds ratios (ORs) with 95%
conﬁdence intervals (CIs).
The χ2 person test was applied for calculating diﬀerences
between numbers of children with and without detectable
cytokines in serum. The results of Student t test were pre-
sentedasarithmeticmeans±SD.TheresultsoftheU-Mann-
Whitney test were presented as median (min-max). In all
analyses a two-tailed signiﬁcance level <.05 was regarded as
statistically signiﬁcant.
8. RESULTS
The NPDR children demonstrated a signiﬁcantly longer du-
ration of the disease in addition to higher HbA1c, albumin
excretion rate, C-reactive protein, as well as systolic blood
pressure than those without retinopathy. There were no sig-
niﬁcant diﬀerences between both groups in the serum cre-
atinine and diastolic blood pressure. Moreover, the NPDR
children demonstrated a signiﬁcantly higher HbA1c, C reac-
tive protein, albumin excretion rate, creatinine in serum, sys-
tolicanddiastolicbloodpressuresascomparedtothehealthy
group (Table 1).K a t a r z y n aZ o r e n ae ta l . 3
Table 1: Clinical parameters of the DM type 1 children and healthy group. Values are presented as means ± SD.
Clinical parameters Children with NPDR Children without retinopathy Healthy group Statistical signiﬁcance
Number of children 21 90 41
Age (years) 15 ±21 4 ±31 4 ±2 NS
NS
Duration of DM (years) 9 ±45 ±3— P<. 001∗
P<. 001∗∗
HbA1c (%) 9.7 ±1.88 .2 ±1.74 .2 ±0.3 P<. 001∗
P<. 001∗∗
C-reactive protein (mg/L) 2.3 ±1.01 .4 ±0.80 .3 ±0.04 P<. 001∗
P<. 001∗∗
Albumin excretion rate (mg/24) 34 ±21 18 ±12 3 ±1 P<. 001∗
P<. 001∗∗
Creatinine in serum (μmol/L) 0.9 ±0.90 .9 ±0.80 .5 ±0.1 NS
P<. 001∗∗
Systolic blood pressure (mm/Hg) 122 ±10 155 ±11 110 ±10 P<. 001∗
P<. 001∗∗
Diastolic blood pressure (mm/Hg) 73 ±10 70 ±96 8 ±8 NS
P<. 001∗∗
∗Diﬀerences between children with nonproliferative retinopathy and without retinopathy.
∗∗Diﬀerences between children with nonproliferative retinopathy and healthy group.
Table 2: Circulating levels of cytokines in serum of DM type 1 children and healthy group. Values are presented as means ±SD.
Level cytokines Children with NPDR Children without retinopathy Healthy group Statistical signiﬁcance
N2 1 9 0 4 1
TNF-α(pg/mL) 1.7 ±1.40 .6 ±0.80 . 0 P<. 001∗
P<. 001∗∗
IL-6 (pg/mL) 3.9 ±1.21 .8 ±0.90 .5 ±0 P<. 001∗
P<. 001∗∗
IL-12 (pg/mL) 1.8 ±1.61 .2 ±1.50 . 0 NS
P<. 001∗∗
∗Diﬀerences between children with nonproliferative retinopathy and without retinopathy.
∗∗Diﬀerences between children with nonproliferative retinopathy and healthy group.
The serum levels of TNF-α a n dI L - 6i nt h eg r o u pw i t h
NPDR were signiﬁcantly higher as compared with children
withoutretinopathy.Ontheotherhand,theIL-12levelswere
higher in the NPDR group with regard to the patients with-
out retinopathy, however the diﬀerence was statistically in-
signiﬁcant. Children without retinopathy were characterized
by signiﬁcantly higher TNF-α, IL-6, as well as IL-12 serum
levels in relation to the healthy controls (Table 2).
As many as 76% of the NPDR children had a detectable
serum level ofTNF-α whilein thegroupwithoutretinopathy
only 34% were TNF-α positive. This stands in clear contrast
to the healthy group which was absolutely (100%) negative
with respect to serum TNF-α.T h ed i ﬀerences between chil-
dren with and without NPDR were statistically signiﬁcant.
However, all the NPDR children (100%) had a detectable
serum level of IL-6 and 70% of children without retinopa-
t h yw e r eI L - 6p o s i t i v e .T h ed i ﬀerences between both diabetic
groupswerestatisticallysigniﬁcant.Inthehealthygrouponly
2.85% were IL-6 positive. There were no diﬀerences between
percentages of the IL-12 positive children in the groups with
NPDR and without retinopathy, 43% and 24%, respectively.
Resultsofthefactorspredisposingtodiabeticretinopathy
development in DM1 children are summarized in Table 3.
9. DISCUSSION
We have examined a group of 111 children diagnosed with
DM type 1, including 21 (26%) children with recognised
nonproliferative diabetic retinopathy. In relation to those
without retinopathy, the NPDR children demonstrated sig-
niﬁcantly longer duration of the disease, they had higher
HbA1c, urine albumin excretion rate, CRP level, as well as
the systolic blood pressure. TNF-α was detectable in 76%
of the NPDR children and only in 34% of the DM type 14 Mediators of Inﬂammation
Table 3: Unadjusted retinopathy risk gradation.
Parameters OR 95% Cl Statistical signiﬁcance
Serum level of TNF-α (pg/mL) 4.01 2.01–7.96 .0001
C-reactive protein (mg/L) 2.55 1.54–4.2 .0001
HbA1c (%) 1.58 1.22–2.06 .0004
Serum level of IL-6 (pg/mL) 1.52 1.11–2.07 .007
Duration of DM (years) 1.39 1.39–1.18 .005
Age (years) 1.25 1.07–1.46 .003
Systolic blood pressure (mm/Hg) 1.08 1.02–1.13 .03
Albumin excretion rate (mg/24) 1.01 1.00–1.03 .03
Diastolic blood pressure (mm/Hg) 1.03 0.98–1.08 .2
NS
Creatinine in serum (μmol/L) 1.0 0.9–1.0 .3
NS
Serum level of IL-12 (pg/mL) 0.9 0.6–1.2 .7
NS
children without retinopathy. Statistical analysis disclosed
TNF-α as the only independent early marker indicating oc-
currence of changes at the fundus of the eye.
In a few studies published in recent years authors re-
ported detectable TNF-α in the serum of children with long-
standing diabetes, however these patients had no concomi-
tant diabetic complications [16–19]. The Chinese scientists
analyzed a group of children of less than 5 years of diabetes
mellitus type 1 duration having no late complications of the
disease [17]. They showed that TNF-α serum levels did not
diﬀer from those of the healthy children. The Italian group
reported results of a study in which TNF-α and IL-6 serum
levels were compared between the groups of children be-
ing less than one year or over ﬁve years from the DM type
1 diagnosis and healthy controls. Children being less than
one year form the disease diagnosis presented higher TNF-α
serum levels in comparison to the other two groups [18]. On
the other hand a diﬀerent group reported that TNF-α serum
level was found lower than in the healthy controls [19].
The mechanism of TNF-α contribution to diabetic
retinopathy is not fully elucidated. It has been suggested that
hyperglycaemia may lead to the activation of proinﬂamma-
tory cytokines that are crucial for micro- and macroangiopa-
thy developments [9, 10]. In diabetic patients an increased
synthesis of the macrophage’s RAGE receptors, which bind
ﬁnal glycation products, has been noted [10]. The RAGE re-
ceptors signalize the proinﬂammatory cytokines’ cascade in-
duction, including TNF-α, IL-6, and IL-12 [9–11]. These cy-
tokines may mediate the synthesis of acute phase proteins
which are able to initiate and support inﬂammatory process
in the vascular wall. As a consequence, an increased expres-
sion of intercellular adhesion molecule-1 (ICAM-1) and vas-
cular adhesion molecule-1 (VCAM-1) on endothelial cells
is induced, which serves as chemoattractants for monocytes
and other inﬂammatory cells [1, 11, 20].
InourstudyserumIL-6levelwasmoreelevatedinNDPR
group than without retinopathy children and similar rela-
tions concerned the IL-6 positive sera in these groups. On
the other hand, IL-6 did not reach a status of an indepen-
dent retinopathy risk factor. The negative role of IL-6 is also
associated with its eﬀect on endothelial dysfunction with an
increased permeability and enhanced expression of adhesion
molecules on these cells [18, 21, 22]. Elevated levels of IL-
6b o t hi ns e r u ma n di nv i t r e o u sﬂ u i dh a v eb e e nd e t e c t e di n
proliferative retinopathy in adult patients [23, 24]. However,
there was no report published in the available literature on
the role of IL-6 at the early stages of the diabetic retinopa-
thy development in DM type 1 children. The NPDR chil-
dren, apart from elevated TNF-α and IL-6 levels, did not dif-
fer in the IL-12 concentration. Formerly, the role of IL-12
as a proinﬂammatory cytokine in the insulin-dependent di-
abetes pathogenesis was shown using the NOD model [12]
and in some limited studies in humans [25, 26]. Winkler et
al. showed that IL-12 may also contribute to the pathogen-
esis of diabetic retinopathy more likely as a part of the con-
secutive immunological response mechanisms rather than a
predisposing factor [26].
On the account of the presented data it appears that,
among the analyzed parameters, TNF-α is the most signif-
icant predictor of damage to the eye apparatus. The early
introduction of the TNF-α antagonists to the treatment of
young patients with DM type 1 who show high serum ac-
tivity of the cytokine may prevent development of diabetic
retinopathy.
ABBREVIATIONS
DM: Diabetes mellitus
NPDR: Nonproliferative diabetic retinopathy
TNF-α: Tumor necrosis factor-alpha
IL-6: Interleukin-6
IL: Interleukin-12
ABPM: Ambulatory blood pressure monitoring
RAGE: Receptor for advanced glycation end product
ICAM-1: Intercellular adhesion molecule-1
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